Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for treating resectable non-small-cell lung cancer:
- Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer (2026) NICE technology appraisal guidance 1127
- Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (2025) NICE technology appraisal guidance 1030
This page was last updated: